Pharmacodynamic Trial on Rocuronium in Obese Patients

Summary

Aim: To optimize the use of rocuronium (a neuromuscular blocking agent) in obese patients undergoing gastric bypass or gastric banding.

Background: During general anaesthesia, a neuromuscular blocking agent is needed to allow surgery and airway management. Optimal dosing is important in order to avoid inadequately muscle relaxation, but also to avoid overdosage, which can result in prolonged anaesthesia and respiratory complications.

Main hypothesis: Rocuronium dosed according to ideal body weight results in shorter duration of action compared to rocuronium dosed according to corrected body weight without prolonged onset time or compromised airway management or surgical demands for muscle relaxation.

Conditions

• Bariatric Surgery

Interventions

DRUG

Rocuronium

0.6 mg/kg given intravenously before intubation

Sponsors & Collaborators

• Rigshospitalet, Denmark

  lead OTHER

Principal Investigators

• Lars S Rasmussen, MD, DMSc · Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark

• Christian S Meyhoff, MD, PhD · Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark

• Casper Claudius, MD, PhD · Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark

• Jørgen Viby-Mogensen, Prof., DMSc · Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark

• Jørgen Lund, MD · Department of anaesthesia, Privathospitalet Hamlet A/S, Denmark

• Morten Jenstrup, MD · Department of anaesthesia, Privathospitalet Hamlet A/S, Denmark

• Anne Marie Sørensen, MD, PhD · Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-10-31

Primary Completion

2008-02-29

Completion

2008-02-29

Countries

• Denmark

Study Locations